Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lansoprazole response in plasma pyrophosphate in pseudoxanthoma elasticum
2016-004021-16Phase 2Active
- Sponsor
- Fundación IMABIS
- Start
- Mar 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of lansoprazole in pseudoxanthoma elasticum (PXE), sponsored by Fundación IMABIS. Primary endpoint: Change in plasma inorganic pyrophosphate and regulatory molecules. Started Mar 2017; status: active.
02
Drugs
lansoprazole
03
Conditions
pseudoxanthoma elasticum (PXE)
Beyond the preview
Go deeper on 2016-004021-16.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2016-004021-16.